Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5h-2,3-benzodiazepine
2. Egyt-341
3. Grandaxin
4. Levotofisopam
5. Tofisopam
6. Tofizopam
1. R-tofisopam
2. Ez15i5d6c1
3. 82059-50-5
4. (5r)-1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5h-2,3-benzodiazepine
5. (+)-(5r)-1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5h-2,3-benzodiazepine
6. Dextofisopam [usan]
7. Dextofisopam (usan/inn)
8. Dextofisopam [usan:inn]
9. Unii-ez15i5d6c1
10. Dextofisopam [inn]
11. Schembl236796
12. Schembl8086913
13. Chembl2107331
14. Dtxsid00231554
15. Zinc608106
16. Db06582
17. D03737
18. Q27277442
19. (5r)-1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5h-2,3-benzodiazepine
20. 5h-2,3-benzodiazepine, 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-, (5r)-
21. 5h-2,3-benzodiazepine, 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl, (5r)
22. Jpu
| Molecular Weight | 382.5 g/mol |
|---|---|
| Molecular Formula | C22H26N2O4 |
| XLogP3 | 3.2 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 6 |
| Exact Mass | 382.18925731 g/mol |
| Monoisotopic Mass | 382.18925731 g/mol |
| Topological Polar Surface Area | 61.6 Ų |
| Heavy Atom Count | 28 |
| Formal Charge | 0 |
| Complexity | 579 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in irritable bowel syndrome (IBS).
Antidepressive Agents
Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems. (See all compounds classified as Antidepressive Agents.)
ABOUT THIS PAGE
23
PharmaCompass offers a list of R-Tofisopam API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right R-Tofisopam manufacturer or R-Tofisopam supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred R-Tofisopam manufacturer or R-Tofisopam supplier.
PharmaCompass also assists you with knowing the R-Tofisopam API Price utilized in the formulation of products. R-Tofisopam API Price is not always fixed or binding as the R-Tofisopam Price is obtained through a variety of data sources. The R-Tofisopam Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A R-Tofisopam manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of R-Tofisopam, including repackagers and relabelers. The FDA regulates R-Tofisopam manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. R-Tofisopam API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A R-Tofisopam supplier is an individual or a company that provides R-Tofisopam active pharmaceutical ingredient (API) or R-Tofisopam finished formulations upon request. The R-Tofisopam suppliers may include R-Tofisopam API manufacturers, exporters, distributors and traders.
R-Tofisopam Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of R-Tofisopam GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right R-Tofisopam GMP manufacturer or R-Tofisopam GMP API supplier for your needs.
A R-Tofisopam CoA (Certificate of Analysis) is a formal document that attests to R-Tofisopam's compliance with R-Tofisopam specifications and serves as a tool for batch-level quality control.
R-Tofisopam CoA mostly includes findings from lab analyses of a specific batch. For each R-Tofisopam CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
R-Tofisopam may be tested according to a variety of international standards, such as European Pharmacopoeia (R-Tofisopam EP), R-Tofisopam JP (Japanese Pharmacopeia) and the US Pharmacopoeia (R-Tofisopam USP).
